CLINICAL IMPACT OF DOSE MODIFICATION AND DOSE INTENSITY ON RESPONSE TO PONATINIB IN PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) LEUKEMIAS

被引：0

作者：

Nicolini, F. E. ^{[1
]}

Cortes, J. E. ^{[2
]}

Kim, D. W. ^{[3
]}

Pinilla-Ibarz, J. ^{[4
]}

le Coutre, P. D. ^{[5
]}

Paquette, R. ^{[6
]}

Chuah, C. ^{[7
]}

Apperley, J. F. ^{[8
]}

Khoury, H. J. ^{[9
]}

Talpaz, M. ^{[10
]}

DiPersio, J. F. ^{[11
]}

DeAngelo, D. J. ^{[12
]}

Abruzzese, E. ^{[13
]}

Rea, D. ^{[14
,15
]}

Baccarani, M. ^{[16
]}

Muller, M. C. ^{[17
]}

Gambacorti-Passerini, C. ^{[18
]}

Lustgarten, S. ^{[19
]}

Rivera, V. M. ^{[19
]}

Haluska, F. G. ^{[19
]}

Guilhot, F. ^{[20
]}

Deininger, M. W. ^{[21
]}

Hughes, T. P. ^{[22
]}

Shah, N. P. ^{[23
]}

Kantarjian, H. M. ^{[2
]}

Hochhaus, A. ^{[24
]}

机构：

[1] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[4] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

[5] Charite, D-13353 Berlin, Germany

[6] Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA

[7] Singapore Gen Hosp, Duke NUS Grad Med Sch, Singapore, Singapore

[8] Univ London Imperial Coll Sci Technol & Med, London, England

[9] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[10] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[11] Washington Univ, Sch Med, St Louis, MO USA

[12] Dana Farber Canc Inst, Boston, MA 02115 USA

[13] Univ Roma Tor Vergata, S Eugenio Hosp, Rome, Italy

[14] Hop St Louis, Serv Malad Sang, Paris, France

[15] Hop St Louis, CIC Clin Invest Ctr, Paris, France

[16] S Orsola Malpighi Univ Hosp, Bologna, Italy

[17] Univ Med, Med Klin 3, Mannheim, Germany

[18] Azienda Osped San Gerardo Univ Milano Bicocca, Unita Ric Clin Ematol, Monza, Italy

[19] ARIAD Pharmaceut Inc, Cambridge, MA USA

[20] Univ Hosp, CHU Poitiers, Poitiers, France

[21] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[22] Inst Med & Vet Sci, Adelaide, SA 5000, Australia

[23] Univ Calif San Francisco, San Francisco, CA 94143 USA

[24] Univ Klinikum Jena, Jena, Germany

来源：

HAEMATOLOGICA | 2014年 / 99卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P894

引用

页码：334 / 334

页数：1

共 50 条

[21] Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
Samra, Bachar
Kantarjian, Hagop M.
Sasaki, Koji
Short, Nicholas J.
Khouri, Rita
Khoury, Joseph D.
Champlin, Richard E.
Kebriaei, Partow
Cortes, Jorge E.
Jorgensen, Jeffrey L.
Wang, Sa A.
Garcia-Manero, Guillermo
Kadia, Tapan M.
Borthakur, Gautam M.
Verstovsek, Srdan
Daver, Naval G.
Montalban-Bravo, Guillermo
Jain, Nitin
Konopleva, Marina Y.
Yilmaz, Musa E.
Naqvi, Kiran
O'Brien, Susan M.
Ravandi, Farhad
Jabbour, Elias
BLOOD, 2019, 134
[22] Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study
Tojo, Arinobu
Kyo, Taiichi
Yamamoto, Kazuhito
Nakamae, Hirohisa
Takahashi, Naoto
Kobayashi, Yukio
Tauchi, Tetsuzo
Okamoto, Shinichiro
Miyamura, Koichi
Hatake, Kiyohiko
Iwasaki, Hiromi
Matsumura, Itaru
Usui, Noriko
Naoe, Tomoki
Tugnait, Meera
Narasimhan, Narayana I.
Lustgarten, Stephanie
Farin, Heinrich
Haluska, Frank
Ohyashiki, Kazuma
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 106 (03) : 385 - 397
[23] A phase II trial of ponatinib and blinatumomab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL)
Short, Nicholas James
Jabbour, Elias
Jain, Nitin
Macaron, Walid
Huang, Xuelin
Montalban-Bravo, Guillermo
Kadia, Tapan M.
Daver, Naval Guastad
Haddad, Fadi
Zoghbi, Marianne
Nasnas, Cedric Christophe
Nasr, Lewis Fady
Mayor, Ejiroghene
Deen, Wuliamatu
Thankachan, Jennifer
Loiselle, Christopher
Garris, Rebecca
Konopleva, Marina
Ravandi, Farhad
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[24] Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph plus ) Leukemia: Results From the PACE Trial
Hochhaus, Andreas
Kim, Dong-Wook
Pinilla-Ibarz, Javier
le Coutre, Philipp
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane
Khoury, H. Jean
Talpaz, Moshe
DiPersio, John F.
DeAngelo, Daniel
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Muller, Martin C.
Gambacorti-Passerini, Carlo
Wong, Stephane
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Tim
Turner, Christopher D.
Haluska, Frank G.
Guilhot, Francois
Deininger, Michael W.
Hughes, Timothy P.
Goldman, John M.
Shah, Neil
Kantarjian, Hagop M.
Cortes, Jorge E.
BLOOD, 2012, 120 (21)
[25] Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib
Sasaki, Yuya
Kantarjian, Hagop M.
Short, Nicholas J.
Wang, Feng
Furudate, Ken
Uryu, Hidetaka
Garris, Rebecca
Jain, Nitin
Sasaki, Koji
Ravandi, Farhad
Konopleva, Marina
Garcia-Manero, Guillermo
Little, Latasha
Gumbs, Curtis
Zhao, Li
Futreal, P. Andrew
Takahashi, Koichi
Jabbour, Elias
LEUKEMIA, 2022, 36 (05) : 1253 - 1260
[26] A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL)
Nguyen, Daniel
Jabbour, Elias
Short, Nicholas
Issa, Ghayas C.
Yilmaz, Musa
Daver, Naval
Pemmaraju, Naveen
Chien, Kelly S.
Masarova, Lucia
Ravandi, Farhad
Jain, Nitin
Deen, Wuliamatu
Zhao, Min
Loiselle, Christopher
Waller, Lourdes
Banks, Glenda
Garris, Rebecca
Kantarjian, Hagop
BLOOD, 2022, 140 : 6127 - 6129
[27] Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice—data from a Belgian registry
Timothy Devos
Violaine Havelange
Koen Theunissen
Stef Meers
Fleur Samantha Benghiat
Alain Gadisseur
Gaëtan Vanstraelen
Hélène Vellemans
Benjamin Bailly
Nikki Granacher
Philippe Lewalle
Ann De Becker
Koen Van Eygen
Mia Janssen
Agnes Triffet
Inge Vrelust
Dries Deeren
Dominiek Mazure
Julie Bekaert
Michael Beck
Dominik Selleslag
Annals of Hematology, 2021, 100 : 1723 - 1732
[28] Nilotinib in patients (pts) with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL) who are resistant or intolerant to imatinib
Ottmann, Oliver G.
Larson, Richard A.
Kantarjian, Hagop M.
le Coutre, Philipp
Baccarani, Michele
Haque, Ariful
Gallagher, Neil
Giles, Francis
BLOOD, 2007, 110 (11) : 828A - 828A
[29] Immunophenotypic Comparison of Philadelphia Chromosome-Like to Philadelphia Chromosome-Positive (Ph plus ) B-Lymphoblastic Leukemia
Choi, Sarah M.
Shao, Lina
Boyer, Daniel
LABORATORY INVESTIGATION, 2018, 98 : 507 - 508
[30] Low-intensity chemotherapy (mini-HCVD) and ponatinib followed by blinatumomab (blina) and ponatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL): A phase II study
Nasr, Lewis Fady
Jabbour, Elias
Haddad, Fadi
Short, Nicholas James
Macaron, Walid
Nasnas, Cedric Christophe
Zoghbi, Marianne
Issa, Ghayas C.
Yilmaz, Musa
Daver, Naval Guastad
Pemmaraju, Naveen
Masarova, Lucia
Ravandi, Farhad
Jain, Nitin
Deen, Wuliamatu
Loiselle, Christopher
Waller, Lourdes
Banks, Glenda
Garris, Rebecca
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →